基准韩国综合股价指数周五上涨1.76%,至3600点以上,在为期七天的Chuseok假期后开盘大幅上涨,对全球人工智能繁荣再次持乐观态度。英伟达支持的Reflection AI以80亿美元的估值融资20亿美元,推动半导体和科技股走高,SK海力士(9.86%)和三星电子(5.84%)领涨,投资者情绪增强。此外,在Celltrion的Eydenzelt生物仿制药获得美国食品药品监督管理局批准后,三星生物制品(0.59%)和Celltrion(0.11%)等制药股小幅上涨。该药物参考了Eylea,针对价值13.33万亿韩元的全球市场,并已在欧洲和澳大利亚获得批准,进一步提振了人们对韩国制药行业的信心。
The benchmark KOSPI climbed 1.76% to above 3,600 on Friday, opening significantly higher after the seven-day Chuseok holiday amid renewed optimism over the global AI boom. Investor sentiment strengthened following news that Nvidia-backed Reflection AI raised $2 billion at an $8 billion valuation, driving semiconductor and technology shares higher, led by SK Hynix (9.86%) and Samsung Electronics (5.84%). In addition, pharmaceutical stocks such as Samsung Biologics (0.59%) and Celltrion (0.11%) edged higher after Celltrion received US FDA approval for its Eydenzelt biosimilar. The drug, referencing Eylea, targets a global market worth KRW 13.33 trillion and has already secured approvals in Europe and Australia, further boosting confidence in South Korea’s pharmaceutical sector.